ONCOZENE
DEAD

Serial Number

86299032

Owner

CeloNova Biosciences, Inc.

Attorney

Kelly P. McCarthy

Filing Date

Jun 3, 2014

Add to watchlist:

No watchlists yet
View on USPTO

ONCOZENE Trademark

Serial Number: 86299032 • Registration: 4754541

ONCOZENE is a trademark filed by CeloNova Biosciences, Inc. on June 3, 2014. The trademark is classified under Class 10 (Medical Apparatus). The application is currently no longer active.

Owner Contact Info

CeloNova Biosciences, Inc. (43 trademarks)

Suite 100
Peachtree City, GA 30269

Entity Type: 03

BOSTON SCIENTIFIC LIMITED (33 trademarks)

The Financial Services Centre
St. Michael BB14004 , BB

Entity Type: 03

VARIAN MEDICAL SYSTEMS, INC. (190 trademarks)

3100 HANSEN WAY
PALO ALTO, CA 94304

Entity Type: 03

Trademark Details

Filing Date

June 3, 2014

Registration Date

June 16, 2015

Published for Opposition

March 31, 2015

Cancellation Date

December 17, 2021

Goods & Services

Medical products, namely, embolic microspheres for use in endovascular therapy, for treatment of hypervascularized tumors and to control and prevent abnormal bleeding; Medical products, namely, embolic microspheres for embolization in the form of particles; Medical products, namely, embolic microspheres in the form of particles to slow or block blood flow for mediating devascularizations; Medical products, namely, embolic microspheres in the form of particles to block blood flow throughout the vasculature system; Medical products, namely, embolic microspheres in the form of particles to treat hemorrhages, arteriovenous malformations, hemangioendothelioma, cerebral aneurysms, muscle hypertrophy, hypertrophic cardiomyopathy, gastrointestinal bleeding, trauma, epistaxis, bone cysts, bone metastases, vertebral metastases, varicoceles, congenital hemangioma, artiovenous fistulae, vena cava, vascular anomalies, priapism, prostatic hematuria, hemoptysis, hemorrhagic cystitis, and post-partum hemorrhage; Medical products, namely, embolic microspheres in the form of particles to prevent or reduce blood flow through any tissue or organ of interest in order to reduce the growths of hypervascular tissues or malignant cells, tumors, lesions, hepatocellular carcinoma, and fibroids; Medical products, namely, embolic microspheres in the form of particles to treat vascular conditions; Medical products, namely, embolic microspheres in the form of embolic particle implants; Medical products, namely, embolic microspheres for treating vascular anomalies of the body

Filing History

CANCELLED SEC. 8 (6-YR)
Dec 17, 2021 C8..
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Jun 16, 2020 REM1
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Feb 5, 2020 ASGN
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Nov 6, 2019 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Nov 6, 2019 REAP
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jan 27, 2016 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jan 27, 2016 REAP
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Jan 27, 2016 ASGN
REGISTERED-PRINCIPAL REGISTER
Jun 16, 2015 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 31, 2015 NPUB
PUBLISHED FOR OPPOSITION
Mar 31, 2015 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 11, 2015 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Feb 20, 2015 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 12, 2015 CNSA
EXAMINER'S AMENDMENT ENTERED
Feb 12, 2015 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Feb 12, 2015 GNEN
EXAMINERS AMENDMENT E-MAILED
Feb 12, 2015 GNEA
EXAMINERS AMENDMENT -WRITTEN
Feb 12, 2015 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 11, 2015 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 11, 2015 CRFA
ASSIGNED TO LIE
Feb 2, 2015 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 23, 2015 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 7, 2014 GNRN
NON-FINAL ACTION E-MAILED
Aug 7, 2014 GNRT
NON-FINAL ACTION WRITTEN
Aug 7, 2014 CNRT
ASSIGNED TO EXAMINER
Aug 7, 2014 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Jun 17, 2014 MDSM
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 16, 2014 NWOS
NEW APPLICATION ENTERED
Jun 6, 2014 NWAP